Crinetics Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent en...
Latest News
4 months ago · zacks.com
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue EstimatesCrinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago.
4 months ago · globenewswire.com
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAnnounced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
4 months ago · prnewswire.com
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
4 months ago · fool.com
Why This Pharmaceutical Stock Jumped Close to 100% This WeekIt is getting acquired by a larger firm in the sector.
4 months ago · 247wallst.com
Why Crinetics Stock Soared 99% This WeekCrinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
4 months ago · zacks.com
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4 months ago · newsfilecorp.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. ("Crinetics Pharmaceuticals" or the "Company") (NASDAQ: CRNX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The investigation concerns whether the Crinetics Pharmaceuticals Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
4 months ago · barrons.com
Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today's MarketAI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.
4 months ago · businesswire.com
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its ShareholdersNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash. Halper Sadeh encourages Crinetics shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Crinetics a.
4 months ago · benzinga.com
Crinetics Pharmaceuticals Stock Doubles After The Close: Here's WhyCrinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex Pharmaceuticals Inc (NASDAQ:VRTX).
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CRNX